Products

Oli
Baymatob
Clinical Decision Support & Reference
Oli is a wearable sensor with FDA Breakthrough Device Designation that uses AI to predict postpartum hemorrhage and identify other maternal and fetal complications, providing clinicians with actionable insights.

See all 1 product →

About Baymatob

Baymatob is an Australian healthcare AI company focused on transforming maternal and fetal health outcomes through its AI-guided maternity sensor, monitoring, and diagnostic platform called Oli. The company aims to address the significant challenges in maternal care, where current monitoring technologies are often decades old and fail to provide early warnings for critical complications. Oli is designed to empower healthcare providers by acquiring, interpreting, and predicting vital information about pregnancy progression and potential risks to both mothers and babies.

Specifically, Baymatob’s flagship product, Oli PPH, is being developed to identify individuals at a higher risk of developing postpartum hemorrhage (PPH) well before birth. PPH is a leading cause of preventable maternal death globally, and Oli PPH aims to provide essential advance warning, potentially an hour prior to blood loss, to allow for proactive clinical interventions and reduce the severity of outcomes such as emergency hysterectomy. The device is a wearable sensor that adheres to the mother’s abdomen, monitoring physiological signals including biopotentials, movement, temperature, and deformation. This technology has received FDA Breakthrough Device Designation, indicating its potential to significantly improve clinical practice. Beyond PPH, Baymatob envisions Oli as a comprehensive platform capable of providing insights into labor onset, time until birth, and early warnings for stillbirth, ultimately aiming to establish a new standard of care in maternal health.

Focus Areas

maternal health fetal health postpartum hemorrhage prediction AI-guided monitoring wearable sensors digital health

Business Intelligence

TechnologyAI-guided wearable sensor and diagnostics platform, cloud-connected digital platform

What Physicians Need to Know

Specialization
Baymatob specializes in AI-guided maternal and fetal diagnostics, with a primary focus on improving health outcomes for mothers and their babies. Their flagship product, Oli, is an AI-guided maternity sensor, monitoring, and diagnostic platform.
Key Differentiators
Baymatob's Oli platform is designed to provide early warnings for serious, treatable complications during pregnancy and labor, such as postpartum hemorrhage (PPH), stillbirth, and uterine rupture. Oli PPH is the only product to have demonstrated the ability to identify women at higher risk of developing postpartum hemorrhage well before they give birth, allowing for proactive clinical actions. The device uses four different sensor types, totaling 10 sensors, to gather complex and unique physiological data, which is then analyzed by machine learning algorithms to provide new clinical insights. It has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Technology Stack
The core of Baymatob's technology is the Oli wearable sensor, which collects minute-by-minute information about the mother's body and baby. This data, including maternal and fetal movements, temperatures, uterine muscle, and cardiac output, is fed into AI and machine learning algorithms to identify patterns and predict future health outcomes. The platform is designed to be non-invasive, waterproof, and user-friendly within clinical workflows.
Impact & Reach
Oli aims to transform maternal healthcare by providing advanced warning for complications, potentially reducing preventable maternal deaths and debilitating outcomes. It also has the potential to expand equity of access to life-changing solutions, particularly in rural and remote areas, by enabling monitoring at home and in community clinics.
Physician Tip

For physicians, Baymatob's Oli platform offers an unprecedented opportunity to move from reactive to proactive care in maternal health. The AI-guided sensor provides real-time, actionable insights and early warnings for critical complications like postpartum hemorrhage, potentially hours before traditional methods. This allows for crucial time to prepare and implement preventative measures, improving workflow efficiency and ultimately leading to safer outcomes for mothers and babies. The non-invasive and user-friendly design also supports women's choices in birth and integrates seamlessly into existing clinical workflows.

While specific integration partners are not detailed, the Oli platform is designed to be a digital platform that uses AI as an enhancement tool. Its ability to provide real-time data and insights suggests potential for integration with existing electronic health record (EHR) systems and other hospital monitoring platforms to streamline data flow and clinical decision-making. The company's focus on expanding equity of access also implies potential for integrations that support remote monitoring and community-based care.

Products by Baymatob

1 product in the directory

Oli
Baymatob
Clinical Decision Support & Reference
Oli is a wearable sensor with FDA Breakthrough Device Designation that uses AI to predict postpartum hemorrhage and identify other maternal and fetal complications, providing clinicians with actionable insights.

What the Web Says

Baymatob is an Australian medical device company focused on improving maternal and fetal health outcomes, particularly by developing a wearable AI-guided device called 'Oli' to predict postpartum hemorrhage (PPH) before birth. The company has completed a 500-patient pilot study for Oli and received Breakthrough Device designation from the US FDA, indicating its potential to transform clinical practice. Reviews for Baymatob itself are limited on major review platforms like G2, Glassdoor, Capterra, and Reddit, with most search results pointing to other companies with similar names. However, information available suggests a positive outlook on their product and mission.

Overall: Positive

Strengths

  • Oli device has received US FDA Breakthrough Device designation, expediting regulatory review.
  • The company's mission is to radically reduce postpartum hemorrhage (PPH) and improve maternal and fetal health.
  • Oli is designed to provide early warnings for severe complications during pregnancy and labor.
  • The device uses innovative sensor technology and AI for comprehensive maternal and fetal monitoring.
  • Baymatob is described as having a team of passionate and diverse individuals.
  • The company aims to transform and reinvent pregnancy and labor healthcare.

Limitations

  • Limited public reviews available for Baymatob as an employer or for its product, Oli, on common review platforms like G2, Glassdoor, Capterra, and Reddit.
  • No specific negative feedback found in the provided search results regarding Baymatob or its product.
  • The Oli device is still in clinical trials and not yet widely available.

Based on reviews from: Alberts, BioSpace, PR Newswire, The University of Sydney, GlobalData

Last updated: 2026-09-19

Videos

News, demos, and interviews about Baymatob.

Loading videos...

Videos load interactively. If none appear, search YouTube for Baymatob →

View all on YouTube

Press & Coverage

Femtech Insider
Australia's Baymatob Receives Government Funding to Advance Maternal Complication Early Warning System
Baymatob received funding from the New South Wales Medical Devices Fund to advance Oli, an AI-powered maternal-fetal health platform for early warning of serious complications in pregnancy and labor. This funding is part of a A$7.4 million round awarded to four medical device companies.
2026-05
Signalbase
Baymatob Raises $6.5M in Series
Baymatob closed a $6.5 million Series A funding round to advance its efforts in empowering clinicians with insights for better patient decisions and helping health systems save costs in maternal care. The company also aims to build Australia's local economy and deep-tech capabilities.
2026-06
NSW Government
$7.4 million investment in ground-breaking medical devices
Baymatob will use A$7.4 million in funding from the Minns Labor Government to finalize the development of 'Oli', its AI-powered maternal-fetal health platform. Oli provides early warning for complications like postpartum hemorrhage, stillbirth, and uterine rupture.
2026-05
Forbes Australia
Sydney's Oli procures $6.5m to monitor the leading cause of preventable maternal death
Oli, formerly Baymatob, closed a $6.5 million Series A3 round with funds from Scale Investors, the University of Sydney, and Clare Ventures to address postpartum hemorrhage. The device has analyzed 17 million maternal heartbeats and monitored almost 1,500 women in clinical studies.
2026-05
Oli Medical (Baymatob)
Oli-PPH Pivotal Clinical Trial - USA Patient Recruitment Commences
Baymatob announced the commencement of patient recruitment in the United States for the pivotal clinical trial of its Oli-PPH Early Warning System. This marks a significant step in validating Oli's ability to provide early warning of postpartum hemorrhage.
2025-12
Woman's Hospital
Woman's Hospital is First in the U.S. to Launch International Study to Improve Maternal Health
Woman's Hospital in Baton Rouge, Louisiana, is the first U.S. site to launch an international study for Baymatob's Oli device, an AI-guided maternal and fetal diagnostics company. The study aims to validate Oli's ability to provide early warning for postpartum hemorrhage.
2026-03
Medical Device Network
Baymatob completes pilot study on AI-guided labour monitoring device Oli
Baymatob completed a pilot study for its AI-guided labor-monitoring device, Oli, which aims to identify individuals at higher risk of developing postpartum hemorrhage (PPH) before birth. The company secured FDA Breakthrough Device Designation for Oli in August 2021.
2023-04
Oli Medical (Baymatob)
US FDA awards Breakthrough Device Designation to Australian labour monitoring device, Oli
Baymatob's Oli, a world-first labor monitoring device, received US Food and Drug Administration (FDA) Breakthrough Device Designation. This designation streamlines the regulatory approval path for Oli, which aims to identify individuals at higher risk of postpartum hemorrhage during labor.
2021-08

Frequently Asked Questions

Baymatob offers the Oli AI-guided maternity sensor, monitoring, and diagnostic platform. Its flagship product, Oli PPH, is designed to identify women at higher risk of postpartum hemorrhage (PPH) before birth, aiming to provide early warning and enable preventative clinical actions to reduce this leading cause of preventable maternal death.
Baymatob's Oli device has received FDA Breakthrough Device Designation from the U.S. Food and Drug Administration. This designation provides an expedited regulatory review path, indicating the device's potential to offer more effective diagnosis for life-threatening conditions. Baymatob is currently conducting pivotal clinical trials in Australia and the US to gather data for regulatory submissions.
While specific pricing details are not publicly available, Baymatob's CEO has indicated that the company will initially sell the hardware and later introduce add-on software modules with AI algorithms. This suggests a potential model that could accommodate different levels of investment and functionality for various healthcare providers.
Although detailed support and training programs are not explicitly outlined, Baymatob's mission is to empower healthcare providers. The company is focused on user-friendly design within clinical workflows to give clinicians time to respond and engage in preventative measures.
Yes, Baymatob is actively engaged in partnerships. They are conducting international clinical trials with institutions like Woman's Hospital in the United States, which is the first US site to launch the study. They also have received funding and support from entities like Australian Unity's Future of Healthcare Fund and the NSW Medical Devices Fund, and are collaborating with research partners globally.
Baymatob was founded in 2013 and has successfully raised significant capital, including a $4.215 million Series A funding round in November 2022 and a $6.5 million Series A funding round in June 2026, with support from investors like Australian Unity's Future of Healthcare Fund. They have also received substantial grants from the NSW Medical Devices Fund and the Australian Government's Medical Research Future Fund. The company has a team of 22 employees and is focused on advancing its technology to address various maternal and fetal complications beyond PPH, indicating a long-term vision for growth and impact in maternal healthcare.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

TimeDoc Health is a healthcare technology and services company that provides virtual care management solutions, primarily focusing on chronic care management (CCM), remote patient monitoring (RPM), and behavioral health integration (BHI). Their platform and services are designed to help healthcare organizations, including primary care providers, health systems, FQHCs (Federally Qualified Health Centers), and Medicare Advantage […]

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.